MediGene reports EndoTAG-1 data

MediGene AG (Xetra:MDG) said 22 mg/m2 weekly EndoTAG-1 plus 70 mg/m2 paclitaxel met the primary endpoint in a Phase II trial to treat triple receptor-negative breast cancer, while 44 mg/m2 twice-weekl...